Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor

Journal of Pharmacology and Experimental Therapeutics

Volumn 281, Issue 3, 1997, Pages 1446-1456

  Dahring, Tawny K ^a   Lu, Gina H ^a   Hamby, James M ^a   Batley, Brian L ^a   Kraker, Alan J ^a   Panek, Robert L ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 7 (3 TERT BUTYLUREIDO) 6 (2,6 DICHLOROPHENYL)PYRIDO[2,3 D]PYRIMIDINE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; PHOSPHATIDYLINOSITIDE; PHOSPHOLIPASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ATHEROSCLEROSIS; AUTOPHOSPHORYLATION; CATALYSIS; DNA FLANKING REGION; DNA SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; GENE SEQUENCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RESTENOSIS; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA; CELLS, CULTURED; ENZYME INHIBITORS; GROWTH SUBSTANCES; HUMANS; MALE; MUSCLE, SMOOTH, VASCULAR; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PYRIDINES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0030921482     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. ALONSO, G., KOEGL, M., MAZURENKO, N. AND COURTNEIDGE, S. A.: Sequence requirements for binding of src family tyrosine kinases to activated growth factor receptors. J. Biol. Chem. 270: 9840-9848, 1995.
2. ANTONIADES, H. N., GALANOPOULOS, T., NEVILLE-GOLDEN, J. AND O'HARA, C. J.: Malignant epithelial cells in primary human lung carcinomas coexpress in vivo platelet-derived growth factor (PDGF) and PDGF receptor mRNAs and their protein products. Proc. Natl. Acad. Sci. U.S.A. 89: 3942-3946, 1992.
3. BENJAMIN, C. W., LINSEMAN, D. A. AND JONES, D. A.: Platelet-derived growth factor stimulates phosphorylation of growth factor receptor-binding protein-2 in vascular smooth muscle cells. J. Biol. Chem. 269: 31346-31349, 1994.
4. BILDER, G. E., KRAWIEC, J. A., MCVETY, K., GAZIT, A., GILON, C., LYALL, R., ZlLBERSTEIN, A., LEVITZKI, A., PERRONE, M. H. AND SCHREIBER, A. B.: Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. Am. J. Physiol. 260: C721-C730, 1991.
5. BORNFELDT, K. E., RAINES, E. W., NAKANO, T., GRAVES, L. M., KREBS, E. G. AND Ross R.: Insulin-like growth factor-1 and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J. Clin. Invest. 93: 1266-1274, 1994.
6. BRIDGES, A. J., ZHOU, H., CODY, D. R., REWCASTLE, G. W., McMICHAEL, A., SHOWALTER, H. D., FRY, D. W., KRAKER, A. J. AND DENNY, W. A: Tyrosine kinase inhibitors: Unusually steep structure-activity relationship for analogs of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J. Med. Chem. 39: 267-276, 1996.
7. BUCHDUNGER, E., ZIMMERMANN, J., METT, H., MEYER, T., MULLKR, M., REGENASS, U. AND LYDON, N.: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. U.S.A. 92: 2258-2262, 1995.
8. BURKE, T. R.: Protein-tvrosine kinase inhibitors. Drugs Future 17: 119-131, 1992.
9. CADENA, D. L. AND GILL, G. N.: Receptor tyrosine kinases. FASEB J. 6: 2332-2337, 1992.
10. CLAESSON-WELSH, L.: Platelet-derived growth factor receptor signals. J. Biol. Chem. 269: 32023-32026, 1994.
11. CLELAND, W. W.: Statistical analysis of enzyme kinetic data. Methods Enzymol. 63: 103-112, 1979.
12. CLOWES, A. W. AND REIDY, M. A.:Prevention of stenosis after vascular reconstruction: Pharmacologic control of intimal hyperplasia: A review. J. Vasc. Surg. 13: 885-891, 1991.
13. CONNOLLY, C., HAMBY, J., SCHROEDER, M., LU, G., PANEK, R., AMAR, A., SHEN, C., KRAKER, A. AND DOHERTY, A.: Structure-activity relationships of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. 211th American Chemical Society Meeting, Abstract no. MEDI-193, 1996.
14. CRICKARD, K., GROSS, J. L., CRICKARD, U., YOONESSI, M., LELE, S., HERBLIN, W. F. AND EIDSVOOG, K.: Basic fibroblast growth factor and receptor expression in human ovarian cancer. Gynecol. Oncol. 55: 277-284, 1994.
15. DOLLE, R. E., DUNN, J. A., BOBKO, M., SINGH, B., KUSTER, J. E., BAIZMAN, E., HARRIS, A. L., SAWUTZ, D. G., MILLER, D., WANG, S., FALTYNEK, C. R., XIE, W., SARUP, J., BODE, D. C., PAGANI, E. D. AND SILVER, P. J.: 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular β-type platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 37: 2627-2629, 1994.
16. ELDER, J. T., FISHER, G. J., LINDQUIST P. B., BENNET, G. L., PITTELKOW, M. R., COFFEY, R. J., ELLINGSWORTH, L., DERYNCK, R. AND VOORHEES, J. J.: Overexpression of transforming growth factor α in psoriatic epidermis. Science 243: 811-814, 1989.
17. FALTYNEK, C. R., WANG, S., MILLER, D., MAUVAIS, P., GAUVIN, B., REID, J., XIE, W., HOEKSTRA, S., JUNIEWICZ, P., LEHR, R., SAWUTZ, D. G. AND MURPHY, D.: Inhibition of T lymphocyte activation by a novel p561ck tyrosine kinase inhibitor. J. Enzyme Inhib. 9: 111-122, 1995.
18. FANTL, W., JOHNSON, D. E. AND WILLIAMS, L. T.: Signalling by receptor tyrosine kinases. Annu. Rev. Biochem. 62: 453-481, 1993.
19. FERNS, G. A. A., RAINES, E. W., SPRUGEL, K. H., MOTANI, A. S., REIDY, M. A. AND Ross, R.: Inhibition of neointimal smooth muscle accumulation after angio-plasty by an antibody to PDGF. Science 253: 1129-1132, 1991.
20. FRIESEL, R. E. AND MACIAG, T.: Molecular mechanisms of angiogenesis: Fibroblast growth factor signal transduction. FASEB J. 9: 919-925, 1995.
21. FRY, D. W., KRAKER, A. J., CONNORS, R. C., ELLIOTT, W. L., NELSON, J. M., SHOWALTER, H. D. H. AND LEOPOLD, W. R.: Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity. Anticancer Drug Design 9: 331-351, 1994a.
22. FRY, D. W., KRAKER, A. J., MCMICHAEL, A., AMBROSO, L. A., NELSON. J. M., LEOPOLD, W. R., CONNORS, R. W. AND BRIDGES, A. J.: A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265: 1093-1095, 1994b.
23. GAZIT, A., YAISH, P., GILON, C. AND LEVITZKI, A.: Tyrphostins. I: Synthesis and biological activity of protein tyrosine kinase inhibitors. J. Med. Chem. 32: 2344-2352, 1989.
24. GOSPODAROWICZ, D., FERRARA, N., HAAPARANTA, T. AND NEUFELD, G.: Basic fibroblast growth factor: Expression in cultured bovine vascular smooth muscle cells. Eur. J. Cell Biol. 46: 144-151, 1988.
25. HAJJAR, D. P. AND POMERANTZ, K. B.: Signal transduction in atherosclerosis: Integration of cytokines and the eicosanoid network. FASEB J. 6: 2933-2941, 1992.
26. HANKS, S. K., QUINN, A. M., HUNTER, T.: The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains. Science 241: 42-52, 1988.
27. HYNES, N. E. AND TERN, D. F.: The biology of the erbB2/neu/HER-2 and its role in cancer. Biochem. Biophys. Acta 1198: 165-184, 1994.
28. JACKSON, C. J., RAINES, E. W., Ross, R. AND REIDY, M. A.: Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Arterioscler. Thromb. 13: 1218-1226, 1993.
29. JACKSON, C. L. AND SCHWARTZ, S. M.: Pharmacology of smooth muscle cell replication. Hypertension 20: 713-734, 1992.
30. JAYE, M., SCHLESSINGER, J. AND DIONNE, C. A.: Fibroblast growth factor receptor tyrosine kinases: Molecular analysis and signal transduction. Biochem. Biophys. Acta 1135: 185-199, 1992.
31. JENSEN, R. A., BEELER, J. F., HEIDARAN, M. A. AND LAROCHELLE, W. J.: Characterization of baculovirus-expressed human α and β platelet-derived growth factor receptors. Biochemistry 31: 10887-10892, 1992.
32. KUNDRA, V., ESCOBEDO, J. A., KAZLAUSKAS, A., KIM, H. K., RHEE, S. G. AND WILLIAMS, L. T. AND ZKTTER, B. R.: Regulation of chemotaxis by the platelet derived growth factor receptor-β. Nature 367: 474-476, 1994.
33. KYPTA, R. M., GOLDBERG, Y., ULUG, E. T. AND COURTNEIDGE, S. A.: Association between the PDGF receptor and members of the src family of tyrosine kinases. Cell 62: 481-492, 1990.
34. LEATHERBARROW, R. J.: GraFit User's Guide, Version 3.0, Erithacus Software Ltd., Staines, UK, 1992.
35. LIBBY, P., SCHWARTZ, D., BROGI, E., TANAKA, H. AND CLINTON S. K.: A cascade model for restenosis: A special case of atherosclerosis progression. Circulation 86: 47-52, 1992.
36. LINDNER, V., GIACHELLI, C. M., SCHWARTZ, S. M. AND REIDY, M. A.: A subpopulation of smooth muscle cells in injured rat arteries expresses plateletderived growth factor-B chain mRNA. Circ. Res. 76: 951-957, 1995.
37. LINDNER, V. AND REIDY, M. A.: Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc. Natl. Acad. Sci. U.S.A. 88: 3739-3743, 1991.
38. LINDNER, V. AND REIDY, M.: Expression of basic fibroblast growth factor and its receptor by smooth muscle cells and endothelium in injured rat arteries. Circ. Res. 73: 589-595, 1993.
39. LYALL, R. M., ZILBERSTEIN, A., GAZIT, A., GILON, C., LEVITZKI, A. AND SCHLESSINGER, J.: Tyrphostins inhibit epidermal growth factor (EGF)-receptor tyrosine kinase activity in living cells and EGF-stimulated cell proliferation. J. Biol. Chem. 264: 14503-14509, 1989.
40. MAJESKY, M. W., REIDY, M. A., BOWEN-POPE, D. F., HART, C. E., WILCOX, J. N. AND SCHWARTZ, S. M.: PDGF ligand and receptor gene expression during repair of arterial injury. J. Cell. Biol. 111: 2149-2158, 1990.
41. OGAWARA, H., AKIYAMA, T. AND WATANABE, S.-I.: Inhibition of tyrosine protein kinase activity by synthetic isoflavones and flavones. J. Antibiot. 42: 340-343, 1988.
42. ONODA, T., ISHIKI, K., TAKEUCHI, T., TATSUTA, K. AND UMEZAWA, K.: Inhibition of tyrosine kinase and epidermal growth factor receptor internalization by lavendustin: A methyl ester in cultured A431 cells. Drugs Exp. Clin. Res. 16: 249-253, 1990.
43. PELICCI, G., LANFRANCONE, L., GRIGNANI, F., MCGLADE, J., CAVALLO, F., FORNI, G., NICOLETTI, I., GRIGNANI, F., PAWSON, T. AND PELICCI, P. G.: A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell 70: 93-104, 1992.
44. PEREZ, R., BETSHOLTZ. C., WESTERMARK, B. AND HELDIN C. H.: Frequent expression of growth factors of mesenchymal cells in human mammary carcinoma cell lines. Cancer Res. 47: 3425-3429, 1987.
45. Ross, R.: Platelet derived growth factor. Lancet 1: 1179-1182, 1989.
46. Ross, R.: Polypeptide growth factors and atherosclerosis. Trends Cardiovasc. Med. 1: 277-282, 1991.
47. Ross, R. R.: The smooth muscle cell. II: Growth of smooth muscle in culture and formation of elastic fibers. J. Cell Biol. 50: 172-186, 1971.
48. SAWUTZ, D. G., BODE, D. C., BRIGGS, G. M., REID, J. R., CANNIFF, P., CALDWELL, L., FALTYNEK, C. R., MILLER, D., DUNN, J. A., DEGARAVILLA, L., GUILES, J. W., WEIGELT, MICHNE, W., TREASURYWALA, A. M. AND SILVER, P. J.: In vitro characterization of a novel series of platelet-derived growth factor receptor tyrosine kinase inhibitors. Biochem. Pharmacol. 51: 1631-1638, 1996.
49. SCHWARTZ, S. M., DEBLOIS, D. AND O'BRIAN, E. R. M.: The intima: Soil for atherosclerosis and restenosis. Circ. Res. 77: 445-465, 1995.
50. SCHWARTZ, R. S., HOLMES, D. R. AND TOPOL, E. J.: The restenosis paradigm revisited: An alternative proposal for cellular mechanisms. J. Am. Coll. Cardiol. 20: 1284-1293, 1992.
51. SITARAS, N. M., SARIBAN, E., BRAVO, M., PANTAZIS, P. AND ANTONIADES, H. N.: Constitutive production of platelet-derived growth factor like proteins by human prostate carcinoma cell lines. Cancer Res. 48: 1930-1935, 1988.
52. THOMPSON, A. M., FRY, D. W., KRAKER, A. J. AND DENNY, W. A.: Tyrosine kinase inhibitors. 2: Synthesis of 2.2́-dithiobis-(1H-indole-3-alkanmides) and investigation of their inhibitory activity against epidermal growth factor receptor and pp60v-src protein tyrosine kinases. J. Med. Chem. 37: 598-608, 1994.
53. TRAXLER, P. M., FURET, P., METT, H., BUCHDUNGER, E., MEYER, T. AND LYDON, N.: 4-(Phenylamino)pyrrolopyrimidines: Potent and selective, ATP site-directed inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem. 39: 2285-2292, 1996.
54. TRAXLER, P. AND LYDON, N.: Recent advances in protein tyrosine kinase inhibitors. Drugs Future 20: 1261-1274, 1995.
55. TRINKS, U., BUCHDUNGER, E. AND FURET, P.: Dianilinopthalimides: Potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem. 37: 1015-1027, 1994.
56. ULLRICH, A. AND SCHLESSINGER, J.: Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212, 1990.
57. VALIUS, M. AND KAZLAUSKAS, A.: Phospholipase C-y and phosphatidylinositol 3 kinase are downstream mediators of the PDGF receptor's mitogenic signal. Cell 73: 321-334, 1993.
58. VLODAVSKY, I., FRIEDMAN, R., SULLIVAN, R., SASSE, J. AND KLAGSBRUN, M.: Aortic endothelial cells synthesize basic fibroblast growth factor, which remains cell associated, and platelet-derived growth factor like protein, which is secreted. J. Cell. Physiol. 131: 402-428, 1987.
59. WARD, W. H. J., COOK, P. N., SLATER, A. M., DAVIES, H., HOLDGATE, G. A AND GREEN, L. R.: Epidermal growth factor receptor tyrosine kinase: Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. 48: 659-666, 1994.
60. WEICH, H. A., IBERG, N., KLAGSBRUN, M. AND FOLKMAN, J.: Expression of acidic and basic fibroblast growth factors in human and bovine vascular smooth muscle cells. Growth Factors 2: 313-320, 1990.
61. WENNSTRöM, S., SIEGBAHN, A., YOKOTE, K., ARVIDSSON, A.-K., HELDIN, C.-H., MORI, S. AND CLAESSON-WELSH, L.: Membrane ruffling and chemotaxis transduced by the PDGF β-receptor require the binding site for phosphatidylinositol-3́-kinase. Oncogene 9: 651-660, 1994.
62. ZIMMERMANN, J., BUCHDUNGER, E., METT, H., MEYER, T., LYDON, N. B. AND TRAXLER, P.: Phenylamino-pyrimidine (PAP)-derivatives: A new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors. Bioorg. Med. Chem. Lett. 6: 1221-1226, 1996.